BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 12571812)

  • 21. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors.
    Hanauske AR; Chen V; Paoletti P; Niyikiza C
    Oncologist; 2001; 6(4):363-73. PubMed ID: 11524555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MTA, A Novel Multitargeted Antifolate: from preclinical to phase I and beyond. Proceedings of a meeting. Ixtapa, Mexico, March 13-15, 1998.
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):1-110. PubMed ID: 10610578
    [No Abstract]   [Full Text] [Related]  

  • 23. Pemetrexed (Alimta): a promising new agent for the treatment of breast cancer.
    Calvert H
    Semin Oncol; 2003 Apr; 30(2 Suppl 3):2-5. PubMed ID: 12722017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pemetrexed safety and dosing strategy.
    Niyikiza C; Hanauske AR; Rusthoven JJ; Calvert AH; Allen R; Paoletti P; Bunn PA
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):24-9. PubMed ID: 12571807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
    Raymond E; Louvet C; Tournigand C; Coudray AM; Faivre S; De Gramont A; Gespach C
    Int J Oncol; 2002 Aug; 21(2):361-7. PubMed ID: 12118332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer.
    Le Chevalier T
    Semin Oncol; 2003 Aug; 30(4 Suppl 10):37-44. PubMed ID: 12947960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pemetrexed for diffuse malignant pleural mesothelioma.
    Manegold C; Aisner J
    Semin Oncol; 2002 Apr; 29(2 Suppl 5):30-5. PubMed ID: 12023790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
    Scagliotti GV; Selvaggi G
    Clin Lung Cancer; 2008; 9 Suppl 3():S122-8. PubMed ID: 19419926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer.
    Wu XY; Huang XE; Cao J; Shi L; Xu X; Qian ZY
    Asian Pac J Cancer Prev; 2014; 15(14):5941-4. PubMed ID: 25081726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pemetrexed (Alimta): a novel multitargeted antifolate agent.
    Adjei AA
    Expert Rev Anticancer Ther; 2003 Apr; 3(2):145-56. PubMed ID: 12722874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer.
    Misset JL
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):36-9. PubMed ID: 11894006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
    Molina JR; Adjei AA
    Clin Lung Cancer; 2003 Jul; 5(1):21-7. PubMed ID: 14596699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pemetrexed: a novel antifolate agent enters clinical practice.
    Kut V; Patel JD; Argiris A
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):511-22. PubMed ID: 15270656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms.
    Coudray AM; Louvet C; Kornprobst M; Raymond E; André T; Tournigand C; Faivre S; De Gramont A; Larsen AK; Gespach C
    Int J Oncol; 2005 Aug; 27(2):553-61. PubMed ID: 16010439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pemetrexed plus carboplatin or oxaliplatin in advanced non-small cell lung cancer.
    Scagliotti GV
    Semin Oncol; 2005 Apr; 32(2 Suppl 2):S5-8. PubMed ID: 15818537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248.
    Alberts SR; Kim GP; Mahoney MR; Gornet MK; Rubin J; Ames M; Goetz MP; Weinshilboum RM; Nicol SJ; Goldberg RM
    Clin Colorectal Cancer; 2007 Jul; 6(8):572-7. PubMed ID: 17681103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pemetrexed in malignant pleural mesothelioma.
    Gatzemeier U
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):26-31. PubMed ID: 15655933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions.
    Calvert H
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):105-8. PubMed ID: 10598564
    [No Abstract]   [Full Text] [Related]  

  • 39. Pemetrexed in front-line chemotherapy for advanced non-small-cell lung cancer.
    Scagliotti GV; Novello S; Crino L; Rosell R
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):32-7. PubMed ID: 15655934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gemcitabine and Pemetrexed disodium in treating breast cancer.
    Adjei AA
    Oncology (Williston Park); 2001 Feb; 15(2 Suppl 3):34-7. PubMed ID: 11252887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.